SecBot SecBot
PRESS-RELEASE ·Filed Nov 4, 2026

NAMS

NewAmsterdam Pharma N.V.
NEUTRAL
Impact 5/10
Horizonweeks Processed12d 16h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The EC approval is a major regulatory milestone but the stock's reaction will depend on the PREVAIL interim analysis result expected in Q1 2027, which is the key catalyst for obicetrapib's cardiovascular outcomes data. Monitor Menarini's European launch execution and the RUBENS Phase 3 top-line data expected around year-end 2026.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$20.93
T+0 close · Nov 4, 2026 · via day close
Latest settled
−1.00%
T+5 · $20.72 · next T+20 in 16d
Vs SPY
−0.09%
α at T+5
Latest observation
−5.52%
T+8 · FF3 residual α
  1. T+0 · Nov 4 $20.93entry
  2. T+1 · 12d ago −9.75%α −5.34% · $18.89
  3. T+5 · 6d ago −1.00%α −0.09% · $20.72
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NewAmsterdam Pharma reported Q3 2026 net loss of $17.4M, significantly narrower than the $72.0M loss in Q3 2025, driven by a $23.1M non-cash gain on warrant revaluation and $19.2M in revenue from Menarini regulatory milestones. The company received European Commission approval for obicetrapib (Ubeslo and Evlarco), its first regulatory approval worldwide, and initiated the SPINOZA Phase 2b Alzheimer's trial. Cash stood at $643.1M at quarter-end.

Key Financial Metrics

EPS
−$0.14
Revenue
$19.2M
est $6.4M · +200.0% · +5406.9% YoY
Free Cash Flow
-$109.9M

Key Facts

  • European Commission granted marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe FDC) in September 2026, the first regulatory approval of obicetrapib worldwide
  • Net loss of $17.4M in Q3 2026 vs $72.0M in Q3 2025, improvement driven by $23.1M non-cash gain on warrant fair value change and $19.2M in revenue from Menarini regulatory milestones
  • Revenue of $19.2M in Q3 2026 vs $0.3M in Q3 2025, entirely from milestone recognition under the Menarini license agreement
  • Cash, cash equivalents and marketable securities of $643.1M at September 30, 2026, down from $728.9M at December 31, 2025
  • PREVAIL cardiovascular outcomes trial interim analysis planned for Q4 2026 with result expected in Q1 2027
  • Menarini plans to launch Ubeslo and Evlarco in Germany by YE2026 and UK in 2027
  • SPINOZA Phase 2b trial in preclinical Alzheimer's disease initiated in September 2026

Financial Impact

Net loss improved by $54.6M YoY; revenue increased by $18.9M; cash burn of $85.8M in 9M 2026; EPS beat consensus by $0.30

revenuenet losscash positionEPS

Risk Factors

  • PREVAIL interim analysis outcome is binary and could significantly impact the stock
  • No product revenue yet; company relies on milestone payments and partnership royalties
  • Cash burn rate of ~$85M per nine months suggests runway of approximately 2 years at current spend
  • European commercial launch depends on Menarini's execution and pricing/reimbursement decisions

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3395208

Track record

8 reports on NAMS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +7.23% at T+5 after the Sep 22, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $18.89 to $18.90 Now $19.46 +3.02% ▲ +0.05% −0.26% vs SPY
  2. Nov 4, 202612d ago Press Release Neutral 5/10 Viewing Entry $20.93 to $18.89 Now $19.46 −7.02% ▼ −9.75% −5.34% vs SPY
  3. Sep 29, 20266w ago 8-K Neutral 4/10 Entry $23.81 to $24.32 Now $19.46 −18.27% ▲ +2.14% +2.35% vs SPY
  4. Sep 22, 20267w ago SC 13D/A Bullish 5/10 Entry $22.68 to $22.74 Now $19.46 −14.20% ▲ +0.26% +0.35% vs SPY
  5. Sep 15, 20268w ago Insider Buy Bullish 5/10 Entry $21.18 to $21.93 Now $19.46 −8.12% ▲ +3.54% +2.41% vs SPY
  6. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $27.42 to $27.67 Now $19.46 −29.03% ▲ +0.91% +1.07% vs SPY
  7. Jul 24, 202616w ago 8-K Bullish 7/10 Entry $29.64 to $30.22 Now $19.46 −34.35% ▲ +1.96% +1.94% vs SPY
  8. Apr 8, 202631w ago Press Release Neutral 5/10 Entry $34.01 to $35.07 Now $19.46 −42.78% ▲ +3.12% +2.54% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 8h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026